

PUBLICATIONS OF TYKS HEMATOLOGY UNIT

2020-2016

2020

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, Itälä-Remes M, Yakoub-Agha I, Labussière-Wallet H, Gallego-Hernanz MP, Deconinck E, Chevallier P, Finke J, Esteve J, Mohty M. Nagler A, et al. *Am J Hematol.* 2020 Jun 12. doi: 10.1002/ajh.25905. Online ahead of print.

Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. Piñana JL, Xhaard A, Tridello G, Passweg J, Kozijn A, Polverelli N, Heras I, Perez A, Sanz J, Berghuis D, Vázquez L, Suárez-Lledó M, Itälä-Remes M, Ozcelik T, Iturrate Basarán I, Karakukcu M, Al Zahrani M, Choi G, Cuesta Casas MA, Batlle Massana M, Viviana A, Blijlevens N, Ganser A, Kuskonmaz B, Labussière-Wallet H, Shaw PJ, Arzu Yegin Z, González-Vicent M, Rocha V, Ferster A, Knelange N, Navarro D, Mikulska M, de la Camara R, Styczynski J; Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation and Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). *J Infect Dis.* 2020 Aug 29;jjaa553. doi: 10.1093/infdis/jjaa553. Online ahead of print.

Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Baron F, Labopin M, Blaise D, Itälä-Remes M, Socié G, Forcade E, Yakoub-Agha I, Gorin NC, Esteve J, Nagler A, Mohty M. Baron F, et al. *Bone Marrow Transplant.* 2020 Sep 4. doi: 10.1038/s41409-020-01051-6. Online ahead of print.

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. Gagelmann N, Eikema DJ, de Wreede LC, Rambaldi A, Iacobelli S, Koster L, Caillot D, Blaise D, Remémy P, Bulabois

CE, Passweg J, Leleu X, Zver S, Kobbe G, Ljungman P, Chevallier P, Ringhoffer M, Martin M, Salmenniemi U, Poiré X, Lenhoff S, Pioltelli P, Mordini N, Delforge M, Garderet L, Schönland S, Yakoub-Agha I, Kröger N. *Bone Marrow Transplant*. 2020 Jul 24. doi: 10.1038/s41409-020-01007-w. Online ahead of print.

F-FDG positron emission tomography/computed tomography of cardiac implantable electronic device infections. Salomäki SP, Saraste A, Kemppainen J, Hurme S, Knuuti J, Nuutila P, Seppänen M, Roivainen A, Airaksinen J, Salo T, Oksi J, Pirilä L, Hohenthal U. *J Nucl Cardiol*. 2020 Jul 31. doi: 10.1007/s12350-020-02256-4. Online ahead of print.

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter GOA study. Turunen A, Partanen A, Valtola J, Ropponen A, Siitonen T, Kuittinen O, Kuitunen H, Putkonen M, Sankelo M, Keskinen L, Savolainen ER, Pyörälä M, Kuittinen T, Silvennoinen R, Penttilä K, Sikiö A, Vasala K, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. *Transfusion*. 2020 Jul;60(7):1519-1528. doi: 10.1111/trf.15820. Epub 2020 Apr 24.

Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Kim D, Park G, Huuhtanen J, Lundgren S, Khajuria RK, Hurtado AM, Muñoz-Calleja C, Cardeñoso L, Gómez-García de Soria V, Chen-Liang TH, Eldfors S, Ellonen P, Hannula S, Kankainen M, Bruck O, Kreutzman A, Salmenniemi U, Lönnberg T, Jerez A, Itälä-Remes M, Myllymäki M, Keränen MAI, Mustjoki S. *Nat Commun*. 2020 May 7;11(1):2246. doi: 10.1038/s41467-020-16115-w.

A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Gamberi B, Berthou C, Hernandez M, Semenzato G, Tholouli E, Hájek R, Caers J, Dimopoulos M, Minnema MC, Andreasson B, Parreira J, Crotty G, Remes K, Kueenburg E, Rosettani B, Di Micco A, Peters S, Bacon P, Blau IW. *Clin Lymphoma Myeloma Leuk*. 2020 May 13:S2152-2650(20)30234-2. doi: 10.1016/j.clml.2020.05.006. Online ahead of print.

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Schmaelter AK, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I,

Forcade E, Cornelissen J, Ganser A, Beelen D, Labussière-Wallet H, Passweg J, Savani BN, Schmid C, Nagler A, Mohty M. *Blood Cancer J.* 2020 Mar 3;10(3):26. doi: 10.1038/s41408-020-0296-3.

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. Giardino S, de Latour RP, Aljurf M, Eikema DJ, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhäuser M, Rössig C, Burkhardt B, Zecca M, Afanasyev B, Michel G, Ganser A, Alseraihy A, Ayas M, Uckan-Cetinkaya D, Bruno B, Patrick K, Bader P, Itälä-Remes M, Rocha V, Jubert C, Diaz MA, Shaw PJ, Junior LGD, Locatelli F, Kröger N, Faraci M, Pierri F, Lanino E, Miano M, Risitano A, Robin M, Dufour C; Severe Aplastic Anemia and Chronic Malignancies Working Parties of European Blood and Marrow Transplantation group. *Am J Hematol.* 2020 Jul;95(7):809-816. doi: 10.1002/ajh.25810. Epub 2020 Apr 21.

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Nagler, A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, Deconinck E, Yakoub-Agha I, Cahn JY, Bourhis JH, Labussière-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M. *Leukemia.* 2020 Apr;34(4):1144-1153. doi: 10.1038/s41375-019-0631-5. Epub 2019 Nov 14.

Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD. Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Volin L, Salmenniemi U, Putkonen M, Buño I, Gallardo D, Itälä-Remes M, Partanen J, Ritari J, Hyvärinen K, et al. *Front Immunol.* 2020 Feb 3;11:19. doi: 10.3389/fimmu.2020.00019. eCollection 2020.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A. *Br J Haematol.* 2020 Feb;188(3):428-437. doi: 10.1111/bjh.16185. Epub 2019 Oct 14.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). González-Barca E, Boumendil A, Blaise D, Trněný M, Masszi T, Finel H, Michieli MG, Bittenbring JT, Gritti G, Snowden JA, Bishton M, Bruno B, de Villambrosia SG, Janikova A, Leleu X, Anagnostopoulos A, Poiré X, Crysandt M, Özkurt ZN, Vandenberghe E, Itälä-Remes M, Cahn JY, Jantunen E, Schroyens W, Maertens J, Esquirol A, Dreger P, Montoto S, Sureda A. *Bone Marrow Transplant.* 2020 Feb;55(2):393-399. doi: 10.1038/s41409-019-0650-x. Epub 2019 Sep 20.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A. *Leukemia.* 2020 Jan;34(1):283-292. doi: 10.1038/s41375-019-0544-3. Epub 2019 Aug 19.

2019

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia. Mäkelä E, Löyttyniemi E, Salmenniemi U, Kauko O, Varila T, Kairisto V, Itälä-Remes M, Westermarck J. *Cancers (Basel).* 2019 Nov 11;11(11). pii: E1774. doi: 10.3390/cancers11111774.

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Luoma S, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen T, Kakko S, Putkonen M, Ollikainen H, Terävä V, Sankelo M, Partanen A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Lievonen J, Selander T, Pelliniemi TT, Ilveskero S, Huotari V, Mäntymaa P, Tienhaara A, Jantunen E, Silvennoinen R. *Ann Hematol.* 2019 Dec;98(12):2781-2792. doi: 10.1007/s00277-019-03815-7. Epub 2019 Oct 31.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A

Systematic Review and Meta-analysis. Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, Bonifazi F, Meijer E, Itälä-Remes M, Marková M, Solano C, Kröger N. *JAMA Oncol.* 2019 Oct 17;5(12):1739-48. doi: 10.1001/jamaoncol.2019.3541. Online ahead of print.

The Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. Taimen K, Salomäki SP, Hohenthal U, Mali M, Kajander S, Seppänen M, Nuutila P, Palomäki A, Roivainen A, Pirilä L, Kemppainen J. *Contrast Media Mol Imaging.* 2019 Aug 29; 2019:9157637. doi: 10.1155/2019/9157637. eCollection 2019.

Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT. Ritari J, Hyvärinen K, Koskela S, Niittyvuopio R, Nihtinen A, Salmenniemi U, Putkonen M, Volin L, Kwan T, Pastinen T, Itälä-Remes M, Partanen J. *Front Immunol.* 2019 Jul 16;10:1625. doi: 10.3389/fimmu.2019.01625. eCollection 2019.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porrás RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N. *Biol Blood Marrow Transplant.* 2019 Nov;25(11):2134-2142. doi: 10.1016/j.bbmt.2019.07.004. Epub 2019 Jul 6.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. McLornan D, Szydło R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger

N, Yakoub-Agha I. Biol Blood Marrow Transplant. 2019 Nov;25(11):2167-2171. doi: 10.1016/j.bbmt.2019.06.034. Epub 2019 Jul 5.

Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Radujkovic A, Dietrich S, Blok HJ, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne JL, Jindra P, Veelken JH, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y. Biol Blood Marrow Transplant. 2019 Oct;25(10):2008-2016. doi: 10.1016/j.bbmt.2019.06.028. Epub 2019 Jul 1.

Post-Transplant Cyclophosphamide versus Antithymocyte Globulin in HLA-Mismatched unrelated Donors transplantation. Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M. Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3.

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia. Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, Sinisalo M. Hum Vaccin Immunother. 2019;15(12):2910-2913. doi: 10.1080/21645515.2019.1627160. Epub 2019 Jul 9.

ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Douglas SPM, Siipola P, Kovanen PE, Pyörälä M, Kakko S, Savolainen ER, Salmenniemi U, Orte K, Kytölä S, Pitkänen E, Porkka K, Kilpivaara O, Wartiovaara-Kautto U. Blood. 2019 Jun 20;133(25):2724-2728. doi: 10.1182/blood-2019-01-896233. Epub 2019 Apr 1.

Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Faraci M, Diesch T, Labopin M, Dalissier A, Lankester A, Gennery A, Sundin M, Uckan-Cetinkaya D, Bierings M, Peters AMJ, Garwer M, Schulz A, Michel G, Giorgiani G, Gruhn B, Locatelli F, Giardino S, Uyttebroeck A, Riolland F, Itälä-Remes M, Dreger P, Shaw PJ, Bordon V, Schlegel PG, Mellgren K, Moraleda JM, Patrick K, Schneider P, Jubert C, Lawitschka A, Salooja N, Basak GW, Corbaciouglu S, Duarte R, Bader P; Pediatric and Transplant Complications Working Parties of the European Society for Blood and Marrow

Transplantation. Biol Blood Marrow Transplant. 2019 Sep;25(9):1786-1791. doi: 10.1016/j.bbmt.2019.05.005. Epub 2019 May 11.

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Cremers EMP, de Witte T, de Wreede L, Eikema DJ, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagkos D, Itälä-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt ZN, Anagnostopoulos A, Jindra P, Robin M, Kröger N. Leuk Lymphoma. 2019 Oct;60(10):2404-2414. doi: 10.1080/10428194.2019.1594215. Epub 2019 Apr 18.

Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation. Ritari J, Hyvärinen K, Koskela S, Itälä-Remes M, Niittyvuopio R, Nihtinen A, Salmenniemi U, Putkonen M, Volin L, Kwan T, Pastinen T, Partanen J. Leukemia. 2019; 33:240-248. doi: 10.1038/s41375-018-0229-3.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208. doi: 10.1016/j.bbmt.2019.03.024. Epub 2019 Mar 28.

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, Maertens J, Wu D, Malladi R, Cornelissen JJ, Huynh A, Bourhis JH, Esteve J, Mohty M, Nagler A. Leukemia. 2019 Aug;33(8):1944-1952. doi: 10.1038/s41375-019-0439-3. Epub 2019 Mar 7.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. Kröger N, Eikema DJ, Köster L, Beelen D, de Wreede LC, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M; Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation. *Br J Haematol.* 2019 May;185(4):725-732. doi: 10.1111/bjh.15819. Epub 2019 Feb 28.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P. *Bone Marrow Transplant.* 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21.

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N. *Haematologica.* 2019 Jun;104(6):1230-1236. doi: 10.3324/haematol.2018.201400. Epub 2019 Jan 17.

Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, Yakoub-Agha I, Bourhis JH, Mailhol A, Mohty M, Savani BN, Nagler A. *Am J Hematol.* 2019 Apr;94(4):431-438. doi: 10.1002/ajh.25395. Epub 2019 Jan 10.

Increased MHC Matching by C4 Gene Compatibility in Unrelated Donor Hematopoietic Stem Cell Transplantation. Clancy J, Ritari J, Lobier M, Niittyvuopio R,

Salmenniemi U, Putkonen M, Itälä-Remes M, Partanen J, Koskela S. *Biol Blood Marrow Transplant.* 2019 May;25(5):891-898. doi: 10.1016/j.bbmt.2018.12.759. Epub 2018 Dec 25.

Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, Passweg J, Ljungman P, Poiré X, Chevallier P, Reményi P, Rambaldi A, Anafasyev B, Fegueux N, Rovira M, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A. *Eur J Cancer.* 2019 Jan;106:212-219. doi:10.1016/j.ejca.2018.11.003. Epub 2018 Dec 6.

Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up. Martelin E, Volin L, Itälä-Remes M, Niittyvuopio R, Lindström V, Heiskanen J, Ruutu T, Nihtinen A. *Bone Marrow Transplant.* 2019 Feb;54(2):334-337. doi: 10.1038/s41409-018-0290-6. Epub 2018 Aug 13.

Raudanpuute ilman anemiaa. (Iron deficiency without anemia). Ebeling F, Sinisalo M, Säily M, Widenius T, Kuittinen T, Itälä-Remes M, Remes K. *Suomen Lääkilehti* 2019; 74: 476-478.

2018

Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT. Ranti J, Kurki S, Salmenniemi U, Putkonen M, Salomäki S, Itälä-Remes M. *PLoS One.* 2018 Sep 20;13(9):e0204136. doi: 10.1371/journal.pone.0204136. eCollection 2018.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N. *Br J Haematol.* 2018; 182: 418-422. doi: 10.1111/bjh.15407.

Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, Itälä-Remes M, Wu D, Mohty M, Nagler A. *Cancer*. 2018 Jun 15;124(12):2523-2533.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten HC, Kroeger N, Mohty M, Nagler A. *J Hematol Oncol*. 2018 Mar 15;11(1):40. doi: 10.1186/s13045-018-0586-4.

Severe neutropenia after rituximab-treatment of multiple sclerosis. Rissanen E, Remes K, Airas L. *Mult Scler Relat Disord*. 2018 Feb 20:3-5. doi: 10.1016/j.msard.2017.12.005. Epub 2017 Dec 12.

Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety. Keto J, Kaartinen T, Salmenniemi U, Castrén J, Partanen J, Hänninen A, Korhonen M, Lähteenmäki K, Itälä-Remes M, Nystedt J. *Mol Ther Methods Clin Dev*. 2018 Feb 8;9:109-118. doi: 10.1016/j.omtm.2018.02.001. eCollection 2018 Jun 15.

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, Itälä-Remes M, Sinisalo M. *Hum Vaccin Immunother*. 2018; 14:1471-1474. doi: 10.1080/21645515.2018.1436424.

Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists. Bjerrum OW, Samuelsson J, Ghanima W, Kauppila M, Andersen CL; Nordic Myeloproliferative Neoplasm Study Group. *Eur J Haematol*. 2018 Feb 10. doi: 0.1111/ejh.13043. [Epub ahead of print]

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT. Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden JA, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N. *Haematologica*. 2018 May;103(5):890-897.

Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors. Pahnke S, Larfors G, Axdorph-Nygell U, Fischer-Nielsen A, Haastrup E, Heldal D, Itälä-Remes M, Johansson JE, Kauppila M, Lenhoff S, Ljungman P, Niittyvuopio R, Sandstedt A, Hägglund H. *J Clin Apher*. 2018 Jun;33(3):226-235. doi: 10.1002/jca.21576.

Hidden genomic MHC disparity between HLA-matched sibling pairs in hematopoietic stem cell transplantation. Koskela S, Ritari J, Hyvärinen K, Kwan T, Niittyvuopio R, Itälä-Remes M, Pastinen T, Partanen J. *Scientific Reports* 2018; 8:5396.

Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013. Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Terävä V, Sinisalo M, Kananen K, Schain F, Castren-Kortegangas P, Järvinen TM, Pisini M, Wahl F, Dixon T, Leval A. *PLoS One*. 2018 Dec 5;13(12):e0208507. doi: 10.1371/journal.pone.0208507. eCollection 2018.

Allogeniset kantasolusiirrot soveltuvat iäkkäillekin. Jokela S, Itälä-Remes M, Salmenniemi U, Putkonen M, Kauppila M, Salmi T, Salomäki S, Remes K. *Lääketieteellinen Aikakauskirja Duodecim* 2018; 134(9): 961-968.

2017

The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In myelodysplastic syndrome / transformed acute myelogenous leukemia: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party. Scheid C, de Wreede L, van Biezen A, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Espiga CR, Peniket A, Sierra J, Mufti G, Crawley C,

Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N. Bone Marrow transplant 2017; 52(11): 1519.

Long-term outcome of the patients with steroid-refractory GVHD treated with unmatched mesenchymal stromal cells. Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Vettenranta K, Korhonen M. Bone Marrow Transplant 2017; 52(4): 606.

Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study.

Kolonen A, Sinisalo M, Huttunen R, Syrjänen J, Aittoniemi J, Huhtala H, Sankelo M, Rintala H, Rätty R, Jantunen E, Nousiainen T, Säily M, Kauppila M, Itälä-Remes M, Ollikainen H, Rauhala A, Koistinen P, Elonen E; Finnish Leukemia Group. Infect Dis (Lond). 2017 Nov - Dec;49(11-12):799-808. doi: 10.1080/23744235.2017.1347814. Epub 2017 Jul 6.

A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients. Roininen S, Laine O, Kauppila M,

Vesanen M, Rämetsä M, Sinisalo M, Jantunen E, Säily M, Rätty R, Elonen E, Wartiovaara-Kautto U. Cancer Med. 2017 Jun;6(6):1275-1285. doi: 10.1002/cam4.1094. Epub 2017 May 15.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N. Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I,

Scheid C, Bloor A, Montoto S, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU. *Leuk Lymphoma*. 2017 Oct;58(10):2356-2362. doi: 10.1080/10428194.2017.1285027. Epub 2017 Feb 7.

Good responses but high TRM in adult patients after MSC therapy for GvHD.

Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, Korhonen M. *Bone Marrow Transplant*. 2017 Apr;52(4):606-608. doi: 10.1038/bmt.2016.317. Epub 2016 Dec 12.

Impact of lenalidomide-based induction therapy on the mobilization of CD34+ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. Partanen A, Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Putkonen M, Sankelo M, Pelkonen J, Mäntymaa P, Varmavuo V, Jantunen E. *Transfusion*. 2017 Oct;57(10):2366-2372. doi: 10.1111/trf.14220. Epub 2017 Jul 5.

2016

A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, Itälä-Remes M, Remberger M, Mattsson J. *Haematologica*. 2016 Nov;101(11):1417-1425. Epub 2016 Aug 4.

Cost analysis of a randomized stem cell mobilization study in multiple myeloma.

Varmavuo V, Silvennoinen R, Anttila P, Säily M, Sankelo M, Putkonen M, Ahonen J, Mahlamäki E, Mäntymaa P, Savolainen ER, Remes K, Jantunen E. *Ann Hematol*. 2016 Oct;95(10):1653-9. doi: 10.1007/s00277-016-2772-1. Epub 2016 Aug 3.

Trombosyyttisiirrot verenvuotojen ehkäisyssä. Ilmakunnas M, Remes K, Hiippala S, Mäkisalo H, Åberg F. *Duodecim*. 2016;132(11):1041-9.

Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.

Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, Terävä V, Putkonen M, Kuittinen T, Pelkonen J, Mäntymaa P, Remes K, Varmavuo V, Jantunen E. *Transfusion*. 2016 Jun;56(6):1394-401. doi: 10.1111/trf.13574. Epub 2016 Apr 4.

Aikuisten akuutin myeloosien leukemian hoito. Järvenpää J, Itälä-Remes M, Kauko T, Salmenniemi U, Kauppila M, Putkonen M, Salmi T, Remes K. *Duodecim*. 2016;132(16):1465-73.

Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML. Impola U, Larjo A, Salmenniemi U, Putkonen M, Itälä-Remes M, Partanen J. *Front Immunol*. 2016 Nov 21;7:523. eCollection 2016.

Soluble CD52 levels mark differential treatment efficacy with chemo-immunotherapy and ibrutinib in patients with CLL Short title for running head: sCD52 marks differential treatment efficacy in CLL. Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van t' Veer MB, Tjønnfjord GE, Itälä-Remes M, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn J, Alemayehu WG, Wittebo SI, Kozak T, Walewski J, Abrahamse-Testroote MCJ. *LeukLymphoma* 2016.

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Vojdeman FJ, Van't Veer MB, Tjønnfjord GE, Itälä-Remes M, Kimby E, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MC, van Oers MH, Geisler CH. *Leuk Lymphoma*. 2017 Mar;58(3):594-600. doi: 10.1080/10428194.2016.1213831. Epub 2016 Aug 2. Erratum in: *Leuk Lymphoma*. 2017 Mar;58(3):758.